Literature DB >> 14710995

Glycoinositolphospholipid from Trypanosoma cruzi: structure, biosynthesis and immunobiology.

Jose O Previato1, Robin Wait, Christopher Jones, George A DosReis, Adriane R Todeschini, Norton Heise, Lucia Mendonça Previato.   

Abstract

The pathogenic protozoan parasite Trypanosoma cruzi expresses on its surface an unusual family of glycoinositolphospholipids (GIPLs) closely related to glycosylphosphatidylinositol (GPI) anchors. Different parasite isolates express distinct GIPLs which fall into two series, depending on the substitution of the third mannosyl residue in the conserved glycan sequence Man4-(AEP)-GlcN-InsPO4 by ethanolamine phosphate or beta-galactofuranose. Although the exact role of these molecules in the cell biology and pathogenicity of T. cruzi remains unknown, the lipid and glycan moieties impart distinct responses to host T and B lymphocytes and phagocytes, overall favouring an immune response permissive to the parasite. The biosynsthesis of GIPLs follows a pathway similar to that observed for GPI anchors. However, a more detailed understanding might enable the development of specific inhibitors of parasite-specific enzymes and lead to novel drugs to ameliorate Chagas disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14710995     DOI: 10.1016/s0065-308x(03)56001-8

Source DB:  PubMed          Journal:  Adv Parasitol        ISSN: 0065-308X            Impact factor:   3.870


  26 in total

Review 1.  Phospholipid and sphingolipid metabolism in Leishmania.

Authors:  Kai Zhang; Stephen M Beverley
Journal:  Mol Biochem Parasitol       Date:  2009-12-23       Impact factor: 1.759

Review 2.  The Trypanosoma cruzi Surface, a Nanoscale Patchwork Quilt.

Authors:  Juan Mucci; Andrés B Lantos; Carlos A Buscaglia; María Susana Leguizamón; Oscar Campetella
Journal:  Trends Parasitol       Date:  2016-11-11

3.  Characterization of the inositol phosphorylceramide synthase activity from Trypanosoma cruzi.

Authors:  Juliana M Figueiredo; Wagner B Dias; Lucia Mendonça-Previato; José O Previato; Norton Heise
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

4.  Specific activation of CD4- CD8- double-negative T cells by Trypanosoma cruzi-derived glycolipids induces a proinflammatory profile associated with cardiomyopathy in Chagas patients.

Authors:  L S A Passos; L M D Magalhães; R P Soares; A F Marques; M do C P Nunes; K J Gollob; W O Dutra
Journal:  Clin Exp Immunol       Date:  2017-07-03       Impact factor: 4.330

5.  Molecular and functional characterization of the ceramide synthase from Trypanosoma cruzi.

Authors:  Juliana M Figueiredo; Deivid C Rodrigues; Rafael C M C Silva; Carolina M Koeller; James C Jiang; S Michal Jazwinski; José O Previato; Lucia Mendonça-Previato; Turán P Urményi; Norton Heise
Journal:  Mol Biochem Parasitol       Date:  2011-12-30       Impact factor: 1.759

6.  Inositolphosphoceramide metabolism in Trypanosoma cruzi as compared with other trypanosomatids.

Authors:  Rosa M De Lederkremer; Rosalía Agusti; Roberto Docampo
Journal:  J Eukaryot Microbiol       Date:  2011-02-21       Impact factor: 3.346

7.  Eukaryotic UDP-galactopyranose mutase (GLF gene) in microbial and metazoal pathogens.

Authors:  Stephen M Beverley; Katherine L Owens; Melissa Showalter; Cara L Griffith; Tamara L Doering; Victoria C Jones; Michael R McNeil
Journal:  Eukaryot Cell       Date:  2005-06

Review 8.  Molecular analysis of early host cell infection by Trypanosoma cruzi.

Authors:  Fernando Villalta; M Nia Madison; Yuliya Y Kleshchenko; Pius N Nde; Maria F Lima
Journal:  Front Biosci       Date:  2008-05-01

9.  Sugar nucleotide pools of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major.

Authors:  Daniel C Turnock; Michael A J Ferguson
Journal:  Eukaryot Cell       Date:  2007-06-08

10.  GPIomics: global analysis of glycosylphosphatidylinositol-anchored molecules of Trypanosoma cruzi.

Authors:  Ernesto S Nakayasu; Dmitry V Yashunsky; Lilian L Nohara; Ana Claudia T Torrecilhas; Andrei V Nikolaev; Igor C Almeida
Journal:  Mol Syst Biol       Date:  2009-04-07       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.